KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

People With Lowest Physical Functioning Scores Showed Greatest Improvement After Tirzepatide Treatment.

Xuan Li, Dachuang Cao, Helene Sapin, Fangyu Wang, Theresa Hunter Gibble, Nedina Kalezic Raibulet, Max Denning, Lee M Kaplan

Obesity (Silver Spring) 34(1) 114-126

PMID41187013
PMCIDPMC12724063
DOI10.1002/oby.70067
发表日期2025-11-04
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:FIGURE 1:非 KM 图;FIGURE 2:生活质量量表图;FIGURE 3:生活质量量表图;FIGURE 4:生活质量量表图;FIGURE 5:生活质量量表图。
摘要

摘要

OBJECTIVE: This post hoc analysis of SURMOUNT trials assessed the association of baseline physical function (PF) with obesity-related complications (ORCs), efficacy measures, and PF. The mechanism of tirzepatide-led improvements in PF was evaluated. METHODS: Outcomes were assessed among participants (SURMOUNT-1 = 2539; SURMOUNT-3 = 579; SURMOUNT-4 = 670) grouped by baseline quartiles (Q) of SF-36v2 PF scores within study (higher scores = better PF). Least-squares mean changes from baseline in efficacy measures and PF were estimated using ANCOVA. Pearson's correlation between weight reduction and improvement in PF was calculated. RESULTS: In SURMOUNT-1, participants with lower baseline PF had more ORCs. Tirzepatide-treated participants showed similar reductions in weight (kg; -20.1% to -22.8%), waist circumference (-17.2 to -20.2 cm), and BMI (-7.2 to -9.0 kg/m2) across quartiles. Participants with lower baseline PF reported greater improvements in PF with tirzepatide (Q1 = 12.5; Q4 = -0.8). Results were similar in SURMOUNT-3 and SURMOUNT-4. A weak to mild correlation was noted between weight reduction and improved PF; the strength of correlation decreased from Q1 to Q4. CONCLUSIONS: Lower baseline PF was associated with a higher prevalence of ORCs. Patients taking tirzepatide experienced substantial weight loss, regardless of their baseline PF. Tirzepatide may improve PF through both weight loss-dependent and -independent mechanisms, especially in those with lower baseline PF. TRIAL REGISTRATION: ClinicalTrials.gov identifiers: SURMOUNT-1, NCT04184622; SURMOUNT-3, NCT04657016; SURMOUNT-4, NCT04660643.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(5,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1Duration of obesity by baseline quartiles of SF‐36v2 Physical Functioning domain score. * p < 0.05; *** p < 0.001 across baseline quartiles based on ANOVA model. Baseline is randomization (Week 0) for SURMOUNT‐1 and SURMOUNT‐3 and lead‐in baseline (Week 0) for SURMOUNT‐4. Q1, first quartile; Q2, second quartile; Q3, third quartile; Q4, fourth quartile; SF‐36v2, Short Form‐36 Version 2 Health Survey acute form. [Color figure can be viewed at wileyonlinelibrary.com ]
非 KM Figure
FIGURE 2Obesity‐related complications. * p < 0.05; ** p < 0.01; *** p < 0.001 across baseline quartiles based on chi‐square test. Baseline is randomization (Week 0) for SURMOUNT‐1 and SURMOUNT‐3 and lead‐in baseline (Week 0) for SURMOUNT‐4. COPD, chronic obstructive pulmonary disorder; IWQOL‐Lite‐CT, Impact of Weight on Quality of Life‐Lite‐Clinical Trials Version; OSA, obstructive sleep apnea; Q1, first quartile; Q2, second quartile; Q3, third quartile; Q4, fourth quartile; SF‐36v2, Short Form‐36 Version 2 Health Survey acute form. [Color figure can be viewed at wileyonlinelibrary.com ]
非 KM Figure
FIGURE 3Change from baseline in efficacy measures at end of study. * p < 0.05 versus placebo. Data are presented as LSM (SE) change from baseline (randomization [Week 0] for SURMOUNT‐1 and ‐3 and lead‐in baseline [Week 0] for SURMOUNT‐4) at Week 72 (SURMOUNT‐1 and ‐3) and Week 88 (SURMOUNT‐4) using ANCOVA with LOCF. In SURMOUNT‐4, the comparator arm received both tirzepatide (Weeks 0–36) and placebo (Weeks 36–88). Thus its results are not presented. IWQOL‐Lite‐CT, Impact of Weight on Quality of Life‐Lite‐Clinical Trials Version; LOCF, last observation carried forward; LSM, least‐squares mean; MTD, maximum tolerated dose; PBO, placebo; Q1, first quartile; Q2, second quartile; Q3, third quartile; Q4, fourth quartile; SF‐36v2, Short Form‐36 Version 2 Health Survey acute form; TZP, tirzepatide. [Color figure can be viewed at wileyonlinelibrary.com ]
非 KM Figure
FIGURE 4Change from baseline in patient‐reported outcomes at end of study by baseline quartiles of SF‐36v2 Physical Functioning domain score. * p < 0.05 versus placebo. Data are presented as LSM (SE) change from baseline (randomization [Week 0] for SURMOUNT‐1 and ‐3 and lead‐in baseline [Week 0] for SURMOUNT‐4) at Week 72 (SURMOUNT‐1 and ‐3) and Week 88 (SURMOUNT‐4) using ANCOVA with LOCF. In SURMOUNT‐4, the comparator arm received both tirzepatide (Weeks 0–36) and placebo (Weeks 36–88). Thus its results are not presented. IWQOL‐Lite‐CT, Impact of Weight on Quality of Life‐Lite‐Clinical Trials Version; LOCF, last observation carried forward; LSM, least‐squares mean; MTD, maximum tolerated dose; PBO, placebo; PRO, patient‐reported outcome; Q1, first quartile; Q2, second quartile; Q3, third quartile; Q4, fourth quartile; SF‐36v2, Short Form‐36 Version 2 Health Survey acute form; TZP, tirzepatide. [Color figure can be viewed at wileyonlinelibrary.com ]
非 KM Figure
FIGURE 5Change from baseline in patient‐reported outcomes at the end of the study by baseline quartiles of IWQOL‐Lite‐CT Physical Function composite score. * p < 0.05 versus placebo. Data are presented as LSM (SE) change from baseline (randomization [Week 0] for SURMOUNT‐1 and ‐3 and lead‐in baseline [Week 0] for SURMOUNT‐4) at Week 72 (SURMOUNT‐1 and ‐3) and Week 88 (SURMOUNT‐4) using ANCOVA with LOCF. In SURMOUNT‐4, the comparator arm received both tirzepatide (Weeks 0–36) and placebo (Weeks 36–88). Thus its results are not presented. IWQOL‐Lite‐CT, Impact of Weight on Quality of Life‐Lite‐Clinical Trials Version; LOCF, last observation carried forward; LSM, least‐squares mean; MTD, maximum tolerated dose; PBO, placebo; PRO, patient‐reported outcome; Q1, first quartile; Q2, second quartile; Q3, third quartile; Q4, fourth quartile; SF‐36v2, Short Form‐36 Version 2 Health Survey acute form; TZP, tirzepatide. [Color figure can be viewed at wileyonlinelibrary.com ]
非 KM Figure